Two investment trusts that have proved their worth
These two investment trusts have earned investors’ confidence since their flotations and remain solid bets, says Max King.

Many investors rightly adopted a wait-and-see attitude when Biopharma Credit (LSE: BPCR) raised $762m in its March 2017 flotation. The prospective return of 8%-9%, including a dividend yield of 6%, looked attractive, but how risky were its returns?
BPCR’s manager, Pharmakon, is a specialist lender to the life-sciences sector, having invested $4.7bn in 40 transactions over 12 years. This, Pharmakon says, is a $1.1trn industry growing at 6% per annum.
The loans to companies are “predominantly secured on approved, commercial-stage products” but the servicing and repayment of the loans is dependent on their success. An average rate of return in double figures implies a material risk of the products not selling.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Thirteen top investments
Pedro Gonzalez de Cosio, CEO of Pharmakon, says that companies have to move fast to capitalise on innovation by spending on research and development (R&D) now. They cannot afford to wait for the cash flow from existing products.
“It’s a race. We, however, are not taking clinical risk. For us, the risk is in projections of future sales from established products. Safety issues and product recalls are very rare and competition from new drugs is highly visible owing to the publication of trial results. With a team of 20, we have the expertise to do the necessary due diligence.”
Four years after flotation, BPCR has made 13 investments, four of which have been repaid with better-than-expected realised returns. The remaining nine are on course to generate annual returns between “high single-digits” and 12%.
A single company, Sarepta, comprises 25% of the portfolio, but it has a market value of $11bn including $1.9bn in cash. “It has $500m of sales at net margins over 70% from three products but has 20 more in the pipeline, so it is spending heavily on R&D.” A fifth of the portfolio is in cash but there is a “very attractive pipeline of deals for 2021”. In 2020, Pharmakon closed just three investments out of 243 screened, but four to six is more normal. The shares trade at $0.97, a 3% discount to net asset value (NAV), and yield 7%.
Another trust, launched in late 2016, that has proved itself is Civitas Social Housing (LSE: CSH). It trades at a 7% premium to NAV, yields 4.7% and has a market value above £700m. It invests in social housing, which it leases to housing associations on long-term, inflation-adjusted terms. These properties are for those in need of “supported living” owing to disabilities, mental-health issues or homelessness. There is a chronic shortage of supply of such accommodation yet local authorities are required to house those in need of it.
Firm foundations
Three housing associations account for 57% of CSH’s income and ten for 94%; 35% of CSH’s balance sheet is financed with low-cost debt but the rental yield of CSH’s portfolio is still around 5.5%, indexed to inflation.
This is expensive finance for housing associations, who have access to much cheaper loans from the public sector. Presumably, their rents are correspondingly elevated but these are paid by the local authority (and indirectly by the government) so they must still offer a good deal compared with the alternatives. CSH investors benefit from the inability or unwillingness of the public sector to drive down the cost of the social housing it is obliged to provide.
It is very hard to see how this could change; there is surely no political appetite to alter the financing structure of the provision of housing to those who can least afford it in order to save the government money. This makes CSH, like BPCR, an attractive long-term proposition for those seeking income plus a bit of capital gain.
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.

Max has an Economics degree from the University of Cambridge and is a chartered accountant. He worked at Investec Asset Management for 12 years, managing multi-asset funds investing in internally and externally managed funds, including investment trusts. This included a fund of investment trusts which grew to £120m+. Max has managed ten investment trusts (winning many awards) and sat on the boards of three trusts – two directorships are still active.
After 39 years in financial services, including 30 as a professional fund manager, Max took semi-retirement in 2017. Max has been a MoneyWeek columnist since 2016 writing about investment funds and more generally on markets online, plus occasional opinion pieces. He also writes for the Investment Trust Handbook each year and has contributed to The Daily Telegraph and other publications. See here for details of current investments held by Max.
-
‘Inheritance tax insurance’ enquiries are soaring – but is it worth it?
Premiums for whole of life insurance can run to £5,000 a month to cover a £300,000 inheritance tax bill, with policies costing more the older you take them out.
-
MPs warn over Lifetime ISAs which could leave savers out of pocket
The Treasury Committee has highlighted confusion around the Lifetime ISA withdrawal charge, which risks consumers losing “a significant part of their savings”
-
The British railway industry is in rude health – here's why investors should jump aboard
The railway industry has bounced back from the devastating impact of the pandemic and is entering a new phase of development – and profitability
-
Unloved alternative trusts are going cheap – should you buy?
Opinion Alternative trusts like infrastructure and real estate funds are trading at huge discounts. Investors should take advantage, says Rupert Hargreaves
-
AGMs: a unique selling point for investment trusts that investors should capitalise on
Opinion Shareholder meetings aren’t just a regulatory requirement – they are a way to communicate with investors
-
Aberforth Smaller Companies Trust: a fund that lets you buy Britain on a triple discount
Opinion If UK stocks return to favour, Aberforth Smaller Companies Trust, a value-focused investment trust, should perform well, says Max King
-
Infrastructure investing: a haven of stable growth amid market turmoil
From booming construction in emerging markets to digital and green transitions, the infrastructure sector offers security, returns and long-term opportunities
-
The costly myth of “sell in May”
Opinion May 2025's strong returns for US stocks have once again shown that putting too much weight on seasonal patterns will only make investors poorer, says Max King
-
Vietnam: a high-growth market going cheap
Opinion The threat of tariffs has shaken Vietnamese stocks, but long-term prospects remain solid, says Max King
-
Who’s driving Tesla?
As Elon Musk steps back from government with his eyes on the stars, investors ask if he’s still behind the wheel at his electric-car maker.